1832 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $72.8M | Buy |
223,345
+79,300
| +55% | +$25.9M | 0.06% | 156 |
|
|
2025
Q1 | $38.9M | Buy |
+144,045
| New | +$38.9M | 0.04% | 211 |
|
|
2024
Q3 | – | Sell |
-545
| Closed | -$132K | – | 673 |
|
|
2024
Q2 | $132K | Hold |
545
| – | – | ﹤0.01% | 651 |
|
|
2024
Q1 | $81.5K | Hold |
545
| – | – | ﹤0.01% | 668 |
|
|
2023
Q4 | $104K | Hold |
545
| – | – | ﹤0.01% | 649 |
|
|
2023
Q3 | $96.5K | Hold |
545
| – | – | ﹤0.01% | 665 |
|
|
2023
Q2 | $104K | Sell |
545
-22,200
| -98% | -$4.22M | ﹤0.01% | 668 |
|
|
2023
Q1 | $4.56M | Sell |
22,745
-368,600
| -94% | -$73.8M | 0.01% | 414 |
|
|
2022
Q4 | $93M | Buy |
391,345
+4,200
| +1% | +$998K | 0.15% | 118 |
|
|
2022
Q3 | $77.5M | Buy |
387,145
+386,600
| +70,936% | +$77.4M | 0.14% | 134 |
|
|
2022
Q2 | $79K | Hold |
545
| – | – | ﹤0.01% | 697 |
|
|
2022
Q1 | $88K | Buy |
+545
| New | +$88K | ﹤0.01% | 726 |
|
|
2020
Q2 | – | Sell |
-20,900
| Closed | -$2.29M | – | 645 |
|
|
2020
Q1 | $2.29M | Buy |
+20,900
| New | +$2.29M | 0.01% | 388 |
|